Psychedelic Passage’s Co-Founder and Facilitator, Nick Levich, talks about the function, purpose and importance of a trip sitter during a psychedelic experience.
Similar Posts
Rick Doblin Interview: Psychedelics and the Soviets, A “Driver’s License” to take Drugs, Curing PTSD
Donate to MAPS: https://maps.org/about-maps/our-team/
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
In today’s episode of Psychedelic Spotlight Podcast, James Hallifax from The Psychedelic Investor, had the pleasure of interviewing Rick Doblin, founder of MAPS. When it comes to psychedelic research, the questions of whether psychedelics can help with mental health, and the de-stigmatization of psychedelics, Rick Doblin is the certified G.O.A.T.
Can MDMA treat PTSD? Rick Doblin (and the science) says YES!
Should psychedelics be legalized? Rick Doblin (and facts and logic) say YES!
Did MDMA save the world from World War III? Rick Doblin says… okay well probably not. But it may have played a role!
To learn more about MAPS and their clinical trial, visit maps.org
While you are there, if you are feeling generous and want to donate to a good cause, MAPS is a charity.
Links:
MDMA and the Soviets
https://thebulletin.org/2021/12/psychedelics-the-newest-tool-in-nuclear-negotiations/
CBS MDMA for Veterans Interview
https://www.cbsnews.com/news/mdma-ecstasy-psychedelics-treating-veterans-ptsd/
Today Show MDMA for Veterans Interview
https://www.today.com/health/mdma-ptsd-study-veteran-shares-experience-rcna4495
#RickDoblin #MDMA #PSYCHEDELICS
New Psychedelic ETF (PSYK) UPDATE: What Does This Mean For MindMed, NUMI & Compass Pathways?
In our previous video, we discussed the upcoming IPO of Horizons Psychedelic ETF (PSYK).
Recently, on January 27th, PSYK began trading on the Canadian NEO Stock Exchange.
In this episode we are going to discuss the psychedelic ETF and what it means for MindMed, NUMI, Compass Pathways and other stocks in the psychedelic sector.
We will cover a few things such as:
– PSYK’s fundamentals
– PSYK’s CEO Steve Hawkins
-Is Horizons ETF actively or passively managed?
– What psychedelic stocks are included in the ETF?
– How often does th ETF reorganize its stock holdings?
– How is the size of the individual stocks’ position decided on?
– Is it worth investing in PSYK now?
– What will happen to MindMed (MMED/MMEDF), Numinus Wellness (NUMI), Compass Pathways (CMPS) and the other stocks once they are included?
***A quick reminder, the psychedelic sector is at a VERY early stage, and all of these companies, large-cap and small cap alike, will need to attract more funding to complete their clinical trials and bring their products to market. PSYK will however contribute to this sector as it will bring more funding to the industry as a whole, which will both help individual companies and the wider mission of treating mental health disorders.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#PSYK #MindMed #MMED
HAVN’s Cluster Headache Treatment BETTER Than Mindmed’s? (HAVN CEO Interview)
HAVN VS. Mindmed – Whose Cluster Headache Treatment Is Better?
Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our “This Week In Psychedelic Stocks” segment.
In light of HAVN’s recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore.
HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind.
Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020.
The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) .
https://havnlife.com/
CSE: HAVN | OTC: HAVLF | FRA: 5NP
#HAVN #HAVNLifeSciences #Mindmed
![MindMed Stock Price Targets [How HIGH can $MMED / $MMEDF Go?]🚀](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-44-600x338.jpeg)
MindMed Stock Price Targets [How HIGH can $MMED / $MMEDF Go?]🚀
Today we are going to discuss my 5 year price targets for MindMed, MMEDF on the American OTC market, MMED on the Canadian Neo market and MMQ on the European Frankfurt Stock exchange.
Piggy backing off of a decades worth of positive research showing that substances like LSD, Ibogaine, psilocybin and MDMA can treat mental health illnesses better than current methods by an order of magnitude, MindMed is in my opinion by far the most advanced psychedelic medicines company that retail investors can buy on the public markets which is why MindMedicine is one of my top psychedelic stocks in 2021.
In this video, we’re going to look at 4 different 5 year price targets for MindMed, and assign them a level of probability. The four cases will be:
1. The 5 year bear case for MindMed’s stock
2. The Neutral case for MindMed LT
3. The bull case price target for MindMed
4. The Super Bull case
Timestamps:
0:00 – Intro
2:54 – The Bear Case for MindMed
5:37 – The Neutral Case/ MindMed’s Stagnation
7:49 – The Bull Case for MMED/MMEDF Stock
10:18 – The Super Bull Case for MindMed
13:08 – Note of Caution Plus Answer to Meor’s Nasdaq question
Just as a brief note, in this video we are going to be using MMEDF, and all figures will be in American dollars
And because this is all going to be speculation, the entirety of the episode will take place in, The Speculation Zone
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews
Digital Therapeutics and Psychedelic Medicines || MindMed ‘s SECRET WEAPON?!?
Digital Therapeutics and Psychedelic Medicines || MindMed’s SECRET WEAPON?!? MindMed (MMED / MMEDF / MMQ) and Atai’s secret weapon lies in the digitalization of psychedelic medicines. MindMed has Albert, their Digital Medicines division, and Atai has their Brain Computer Interface.
Instead of doing our usual “This Week In Psychedelic Stocks episode”, I decided to discuss the article entitled “Digital Therapeutics: Optimizing Psychedelics Therapies With Next-Generation IP” as it pertains to MindMed and Atai and because there wasn’t a lot of interesting news for our usual Psychedelic segment.
Why should investors in psychedelic stocks be deeply interested in these technological advancements? According to Jeff Nielson, there’s two reasons.
1.Generally, next-generation digital technology (which includes the introduction of AI) is already pioneering a tech revolution in healthcare.
2.Specifically, psychedelics-based therapies are one of the areas of medical treatment that will benefit the most from this technology.
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
If you wish to collaborate, send us an email at:
thepsychedelicinvestor@gmail.com
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Time Stamps:
0:00 – Intro
10:08 – Implications for MindMed and Atai
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MindmedStock #MMEDNews